Lipella's new drug shows promise in treating oral lichen planus, leading to a significant stock surge.

Lipella Pharmaceuticals has reported successful Phase 2a trial results for LP-310, a drug treating oral lichen planus, showing significant improvements in pain, inflammation, and ulceration with no serious side effects. The company's stock surged over 65% in pre-market trading following the announcement. Further trials with higher doses are ongoing.

1 month ago
6 Articles